Primary Central Nervous System Vasculitis Following Alemtuzumab Treatment for Multiple Sclerosis: A Case Report and Literature Review.
Neurologist
; 28(4): 270-272, 2023 Jul 01.
Article
in En
| MEDLINE
| ID: mdl-36728655
ABSTRACT
INTRODUCTION:
Cerebral vasculitides are often devastating conditions that require immediate diagnosis and treatment. CASE REPORT We report a pathologically proven clinical case of primary central nervous system vasculitis in a 50-year-old man with a diagnosis of relapsing-remitting multiple sclerosis after alemtuzumab therapy, which required additional immunosuppression to control this life-threatening condition.CONCLUSION:
In patients presenting subacute neurological deterioration after alemtuzumab therapy, primary central nervous system vasculitis should be considered as a differential diagnosis among other autoimmune conditions.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Multiple Sclerosis, Relapsing-Remitting
/
Multiple Sclerosis
Type of study:
Diagnostic_studies
Limits:
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Neurologist
Journal subject:
NEUROLOGIA
Year:
2023
Document type:
Article